Global Irritable Bowel Syndrome (IBS) Treatment Market Size, Share, Analysis, Industry Report and Forecast 2020-2026

The global irritable bowel syndrome (IBS) treatment market is projected to exhibit a significant growth, at a CAGR of around 9.5%, during the forecast period. The disturbance in the function of bowel leads to the occurrence of functional gastrointestinal disorder or say IBS. There are few medications available in the market that offer relief to the disorder. Along with the medications, there are several therapies being introduced in the IBS treatment market which are subjected to treat the syndrome. Stem cell therapy is one among those therapies that has been shown a significant relief in the condition of IBS. The increased understanding of the syndrome followed with immunopathology is aiding the development of new targeted treatment solutions for IBS, which includes the use of stem cell treatment, as they have a capability of modulating the immune system. 

To Request a Sample of our Report on Global Irritable Bowel Syndrome (IBS) Treatment Market:  https://www.omrglobal.com/request-sample/irritable-bowel-syndrome-ibs-treatment-market

The researchers of Copenhagen have reported the success in the IBS treatment in mice, via using its stem cells, to repair certain damage to the colon. The use of stem cell transplants for the treatment of immune systems has found to be successful in treating IBS. At present, there are two types of stem cells that are particularly used in the IBS treatment, namely, allogeneic stem cells and autologous stem cells. Among these two types, the allogeneic stem cells are considered more preferably over autologous stem cells for the IBS treatment. Allogeneic stem cells can be directly injected into the colon or infused through an IV drip. 

 In April 2019, Children’s Hospital of Fudan University in China offered a stem cell therapy to a new-born baby suffering with IBS. The hospital was successful in stem cell transplant of a baby in 2015, followed to which, the hospital decided to treat eight other children suffering with the same condition. The stem cell transplants were performed with relatively reduced chemotherapy condition, with an aim to lessen the toxicity of the process for the patients. Therefore, such successful stories related with the stem cell therapy in the treatment of IBS is further expected to propel the IBS treatment market growth during the forecast period. 

 It is expected that the introduction of stem cell therapy in the treatment of irritable bowel syndrome will offer a chance to overturn the condition in patients dealing with mild, moderate or severe pain of IBS. Though, till date, the use of stem cell therapy has not received a wide FDA approval, and more of it is an experimental process. In addition, the use of stem cells in the IBS treatment entirely depends on the physician that have experienced with the use of allogeneic stem cells, through which, the IBS patients can achieve positive health outcomes.

 (Get 15% Discount on Buying this Report)

A full Report of Global Irritable Bowel Syndrome (IBS) Treatment Market is Available at:  https://www.omrglobal.com/industry-reports/irritable-bowel-syndrome-ibs-treatment-market

 Global IBS treatment Market-Segmentation

 By Type

·        IBS-Constipation

·        IBS-Diarrhea

·        IBS-Mixed

·        IBS-Unsubtyped

By Drug Class

·        Eluxadoline

·        Linaclotide

·        Lubiprostone

·        Others (Rifaximin) 

Global IBS treatment Market– Segment by Region 

North America

·        United States

·        Canada

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan

·                  South Korea

·                  Rest of APAC

Rest of The World

Company Profiles

·        Abbott Laboratories

·        Alfasigma S.p.A.

·        Allergan PLC

·        Ardelyx, Inc.

·        Astellas Pharma, Inc.

·        AstraZeneca PLC

·        Bausch Health Companies Inc.

·        GlaxoSmithKline PLC

·        Ironwood Pharmaceuticals, Inc.

·        Lexicon Pharmaceuticals, Inc.

·        Luoxin Pharmaceutical Group Co., Ltd.

·        Mallinckrodt PLC

·        Sebela Pharmaceuticals, Inc. (LOTRONEX)

·        Synthetic Biologics, Inc.

·        Takeda Pharmaceutical Co. Ltd.

Reasons to Buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @  https://www.omrglobal.com/report-customization/irritable-bowel-syndrome-ibs-treatment-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

Comments

Popular posts from this blog

European Data Backup and Recovery Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

Insect Repellent Market Is Likely to Experience a Tremendous Growth by 2031

Asia-Pacific Urban Air Mobility Market Growth, Size, Share, Industry Report and Forecast 2019-2025